Concomitant Sjögren’s Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis

Table 4

Liver-related adverse events at the end of observation.

	PBC(N=226)	PBC/SS(N=56)	P value
Death (%)	9(4.0)	2(3.6)	0.877
HCC (%)	2(0.8)	1(1.8)	0.557
Liver transplantation (%)	2(0.8)	0(0)	0.481
Liver-related adverse events (%)	13(5.8)	3(5.4)	1.000

HCC, hepatocellular carcinoma; SS, Sjögren’s syndrome; and PBC, primary biliary cholangitis.